Vitamin E is one of the oldest names in the vitamin aisle, and Japan’s Foods with Nutrient Function Claims system gives it a specific, government-fixed function statement that brands abroad notice and want to borrow.
This guide is for brand owners planning a vitamin E product made in Japan. It covers what the large human trials actually found, what Japan’s fixed labelling system allows, how the ingredient is formulated, and what to fix before asking for a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a vitamin E product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
Two large, long-term randomised trials of high-dose vitamin E found no benefit for the outcomes they targeted — one found no reduction in cancer or major cardiovascular events and more heart failure, the other a statistically significant increase in prostate cancer — which is the honest starting point for any vitamin E product.
| Study | Design | Reported result |
|---|---|---|
| SELECT trial, JAMA 2011 (PMID 21990298) | Randomised, placebo-controlled trial, 34,887 relatively healthy men (aged 50+ for black men, 55+ for others) in the primary analysis, synthetic vitamin E (400 IU/day of all-rac-alpha-tocopheryl acetate), selenium, both, or placebo, with planned follow-up of 7 to 12 years | Vitamin E alone significantly increased prostate cancer risk (hazard ratio 1.17; 99% CI, 1.004–1.36; P = .008); selenium alone and the combination did not significantly change it |
| HOPE-TOO trial, JAMA 2005 (PMID 15769967) | Randomised, double-blind, placebo-controlled extension trial, natural-source vitamin E (400 IU/day), median 7 years, people aged 55+ with vascular disease or diabetes (a trial in people with a disease) | No reduction in cardiovascular events, cancer or death; higher risk of heart failure (RR 1.13; 95% CI, 1.01–1.26; P = .03) and hospitalisation for heart failure (RR 1.21; 95% CI, 1.00–1.47; P = .045) |
| PIVENS trial, NEJM 2010 (PMID 20427778) | Randomised, double-blind, placebo-controlled treatment trial in 247 adults without diabetes who had a diagnosed liver disease (nonalcoholic steatohepatitis, NASH): vitamin E (800 IU/day) vs a prescription drug (pioglitazone) vs placebo, 96 weeks | Liver tissue features improved in more patients on vitamin E than on placebo (43% vs 19%; P = .001), with no significant improvement in fibrosis; this is a disease-treatment result, not evidence for a supplement |
Four points to keep in view:
- Dose. All three trials used 400–800 IU/day of vitamin E — far above the amounts on ordinary Japanese vitamin E labels, and a different question from whether a modest daily amount does any harm or good.
- Population. SELECT enrolled healthy men; HOPE-TOO enrolled people already living with vascular disease or diabetes; PIVENS enrolled adults with a diagnosed liver disease, NASH. None of these results transfer to a general wellness claim for healthy supplement users.
- Direction of the findings. SELECT and HOPE-TOO are large, well-known negative or concerning trials, not fringe results. Any vitamin E marketing that leans on “protects the heart” or “prevents cancer” is contradicted by them.
- The one positive result is disease-specific. PIVENS is a medical treatment trial in patients with a diagnosed liver disease, run under medical supervision and compared against a prescription drug, at a dose most food-type products do not use. It says nothing about healthy people and must never become an antioxidant, liver-health or disease claim for a supplement.
Checked against the published abstracts on 13 October 2026.
What Japanese products say
Japan allows a fixed, modest antioxidant statement for vitamin E at low, self-certified daily amounts — nothing like the doses used in the trials above.
Vitamin E is one of the nutrients covered by Japan’s Foods with Nutrient Function Claims system (栄養機能食品), under the Food Labelling Standards (食品表示基準, Appendix 11). This is a self-certification system: nothing is notified to the government and the product is not individually reviewed. The seller simply formulates within a fixed daily-amount range and uses only the fixed wording set by the Consumer Affairs Agency (CAA) — it cannot vary that wording. The standard was revised with effect from 1 October 2026.
For vitamin E, the CAA’s fixed range and wording from 1 October 2026 are (the English is our translation of the official Japanese):
- Daily amount range: lower limit 1.95 mg, upper limit 150 mg. This upper limit is a labelling ceiling for the daily serving amount — it is not a medical safety tolerable upper intake level, and it should not be described as one.
- Function claim (fixed wording, cannot be altered): “Vitamin E is one of the nutrients that help protect cells through antioxidant action.” (ビタミンＥは、抗酸化作用により細胞を保護するのを助ける栄養素のひとつです。)
- Mandatory caution wording: “This product does not cure disease or further promote health through excessive intake. Follow the daily recommended amount.”
- Mandatory disclosure: “Unlike Foods for Specified Health Uses, this product has not been individually reviewed by the Commissioner of the Consumer Affairs Agency.”
- Before the revision, and the transition period: until 30 September 2026 the lower limit was 1.89 mg (the upper limit was the same 150 mg) and the wording was “Vitamin E is a nutrient that, through its antioxidant action, protects lipids in the body from oxidation and helps maintain the health of cells.” Processed foods manufactured, processed or imported by 31 March 2030 may still follow the previous standard; a new product is best designed to the revised figure and wording.
Two lessons for a brand abroad:
- The Japanese function claim is deliberately narrow. It describes an antioxidant role in protecting cells, at a labelling dose that tops out at 150 mg. It is not a cardiovascular or cancer-prevention claim, and the trial evidence above is a reason not to stretch it into one.
- Japanese function wording is not a global endorsement. It is a Japanese labelling mechanism, self-certified by the seller, for products sold in Japan. Your label abroad follows your own market’s rules, and outside Japan you cannot use the CAA’s exact wording at all.
Source: Consumer Affairs Agency, Appendix 11 to the Food Labelling Standards as revised with effect from 1 October 2026, and the Consumer Commission’s August 2026 comparison of the current and revised figures and wording.
💬 Need an evidence summary for your regulatory adviser that separates the Japanese labelling rules from the trial evidence? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe vitamin E as an antioxidant nutrient at a stated amount, never as protection against a specific disease.
| Safer wording | Wording to avoid |
|---|---|
| ”Contains vitamin E, a nutrient with an antioxidant role" | "Protects the heart”, “prevents cancer”, “anti-ageing" |
| "Formulated at [x] mg per serving” with the amount stated | Implying the SELECT or HOPE-TOO trial doses were tested for safety or benefit in a food supplement |
| ”An essential nutrient that supports cell health" | "Clinically proven” without naming the study, its population and its dose |
How vitamin E is formulated
Vitamin E is fat-soluble and oxidation-sensitive, so the chemical form and the packaging matter as much as the dose.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Soft capsule | Suits the oil-based natural tocopherol form; easy to dose precisely | Shell material and oxygen barrier |
| Hard capsule or tablet | Uses a dry, esterified form (e.g. tocopheryl acetate); combines easily with other vitamins | Esterified forms need to be released and converted in the body |
| Powder blend | For multivitamin or mineral-and-vitamin combination products | Vitamin E is one of the more oxidation-prone components in a blend |
| Oil or liquid drop | Niche format, sometimes for specific dosing needs | Stability and packaging against light and oxygen |
Decisions that shape the specification:
- Natural or synthetic form. Natural vitamin E (d-alpha-tocopherol) and synthetic vitamin E (dl-alpha-tocopherol, as used in SELECT and HOPE-TOO) differ in source and in how potency is measured (IU vs mg). Ask the supplier which form and which measurement the specification uses.
- Ester form. Tocopheryl acetate and tocopheryl succinate are common stabilised forms for dry dosage formats; ask how the material is measured and converted to free tocopherol.
- Amount per serving. If the product is positioned as a Japanese Foods with Nutrient Function Claims item, the amount must sit within the CAA’s fixed 1.95–150 mg range (1.89–150 mg for products still made under the previous standard during the transition to 31 March 2030) and use only the fixed wording. If not, the amount is a separate decision from your own market’s rules — do not use trial doses (400–800 IU) as a benchmark for a food-type product.
- Companion ingredients. Vitamin E is often paired with other antioxidant nutrients, such as vitamin C or selenium — the SELECT trial itself tested vitamin E with and without selenium. Each companion needs its own check against Japanese food law.
- Packaging and stability. Vitamin E oxidises on exposure to light, heat and oxygen. Oxygen-barrier packaging and appropriate encapsulation protect shelf life.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Vitamin E itself is a routine food ingredient in Japan. The risk in a vitamin E formula usually sits in companion ingredients — some botanical antioxidants sold freely elsewhere are treated as medicines in Japan. See the Japan-made supplement OEM page, and compare with our astaxanthin guide, another antioxidant ingredient, and our GABA guide for a second example of reading trial evidence honestly rather than following the marketing.
Before you ask for a quotation
A factory can quote accurately once the form, the amount, the companions and the packaging are fixed.
- Vitamin E form (natural or synthetic) and ester type
- Amount per serving and servings per pack
- Dosage form
- Companion ingredients and their amounts
- Packaging and light/oxygen protection
- Countries you will sell in, and first order and annual volume
💬 Ready to design a Japan-made vitamin E product? Send us the concept — form, amount, companion ingredients and the countries you will sell in.
Frequently asked questions
1. Does vitamin E prevent cancer or heart disease?
No reliable large trial supports that. The SELECT trial found a significant increase in prostate cancer risk with 400 IU/day vitamin E, and the HOPE-TOO trial found no cardiovascular benefit and a higher risk of heart failure at the same dose. Avoid disease-prevention wording for a vitamin E product.
2. Why do Japanese products carry a vitamin E claim then?
Japan’s Foods with Nutrient Function Claims system allows a fixed, narrow antioxidant statement at a self-certified daily amount between 1.95 mg and 150 mg (1.89 mg was the lower limit before the October 2026 revision) — far below the 400–800 IU used in the trials above, and not a disease-prevention claim.
3. Is there any positive trial evidence for vitamin E at all?
The PIVENS trial found that 800 IU/day vitamin E improved liver tissue features more often than placebo in patients with a diagnosed liver disease, NASH. That is a medical treatment trial in people with a disease, not evidence for healthy people and not a basis for any antioxidant, liver-health or anti-ageing claim on a food supplement.
4. How much vitamin E is considered safe?
The US NIH Office of Dietary Supplements lists a Tolerable Upper Intake Level of 1,000 mg/day for adults from supplemental vitamin E, based on bleeding risk, including for people on anticoagulant medication. This is a medical safety figure, separate from Japan’s 150 mg labelling ceiling for its function claim.
5. Should I use natural or synthetic vitamin E?
Both are used in foods, but they differ in source and in how potency is measured (IU vs mg). The SELECT and HOPE-TOO trials used different forms and reported different outcomes, so ask your supplier which form and measurement basis its specification uses, and match it to the amount you intend to state.
Sources: “Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)”, JAMA 2011;306(14):1549-1556 (PMID 21990298); “Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer: A Randomized Controlled Trial” (HOPE and HOPE-TOO Trial Investigators), JAMA 2005;293(11):1338-1347 (PMID 15769967); “Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis” (PIVENS), New England Journal of Medicine 2010;362(18):1675-1685 (PMID 20427778); US National Institutes of Health, Office of Dietary Supplements, Vitamin E Fact Sheet for Health Professionals; Consumer Affairs Agency, Food Labelling Standards Appendix 11 as revised with effect from 1 October 2026 (food_labeling_cms201_261001_02.pdf, caa.go.jp); Consumer Commission food labelling subcommittee, material 2 of 6 August 2026 on the revision of Foods with Nutrient Function Claims (260806_shiryou2.pdf, cao.go.jp). Checked on 13 October 2026.